Acquisition by Teofilo Raad of 34900 shares of Pulmatrix subject to Rule 16b-3

PULM Stock  USD 6.64  0.70  9.54%   
About 53% of Pulmatrix's investor base is interested to short. The analysis of overall sentiment of trading Pulmatrix stock suggests that many investors are impartial at this time. Pulmatrix's investing sentiment overview a quick insight into current market opportunities from investing in Pulmatrix. Many technical investors use Pulmatrix stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Pulmatrix Inc director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Pulmatrix insider trading alert for grant of stock option right to buy by Teofilo Raad, Chief Executive Officer, on 30th of January 2023. This event was filed by Pulmatrix Inc with SEC on 2023-01-30. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Pulmatrix's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Pulmatrix's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Pulmatrix Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Pulmatrix can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Pulmatrix Fundamental Analysis

We analyze Pulmatrix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pulmatrix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pulmatrix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Operating Margin

Operating Margin Comparative Analysis

Pulmatrix is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Pulmatrix Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pulmatrix stock to make a market-neutral strategy. Peer analysis of Pulmatrix could also be used in its relative valuation, which is a method of valuing Pulmatrix by comparing valuation metrics with similar companies.

Peers

Pulmatrix Related Equities

AKTXAkari Therapeutics   8.04   
0%
85.0%
CTMXCytomX Therapeutics   3.92   
0%
41.0%
MBRXMoleculin Biotech   2.97   
0%
31.0%
ASMBAssembly Biosciences   1.25   
0%
13.0%
ACHLAchilles Therapeutics   0.93   
0%
9.0%
CAPRCapricor Therapeutics   0.16   
1.0%
0%
CRNXCrinetics Pharmaceuticals   0.81   
8.0%
0%
BPTHBio Path   3.75   
39.0%
0%
SLNOSoleno Therapeutics   5.61   
59.0%
0%
TILInstil Bio   9.39   
100.0%
0%
When determining whether Pulmatrix is a strong investment it is important to analyze Pulmatrix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pulmatrix's future performance. For an informed investment choice regarding Pulmatrix Stock, refer to the following important reports:
Check out Pulmatrix Hype Analysis, Pulmatrix Correlation and Pulmatrix Performance.
To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.64)
Revenue Per Share
3.119
Quarterly Revenue Growth
(0.16)
Return On Assets
(0.30)
Return On Equity
(0.59)
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.